Alexion concedes to activists, joins forces on director search

handshake
Elliott is reportedly looking to put more biotech experience on Alexion's board.

Alexion and activist investor Elliott Management are putting their differences aside.

The two parties have agreed to “work collaboratively” to find a new member for Alexion’s board, they said late Tuesday. Alexion had announced back in November that it was looking to fill an open seat.

RELATED: Activists press Alexion for stepped-up guidance, boardroom edits: report

Virtual Roundtable

ESMO Post Show: Highlights from the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields. Register today.

The agreement follows a December report that Elliott had built up a stake in the rare-disease drugmaker and was looking for a bigger effort from the company’s leaders to boost share prices. The fund also wanted to see more biotech experience on Alexion’s slate of directors, according to The New York Timesparticularly now that Ludwig Hantson, the former helmsman of Baxalta, had filled key leadership positions with his pharma peers.

"This agreement is in line with our ongoing efforts to maintain active and constructive dialogue with all of our shareholders and to identify a new board member with a proven track record of building value,” Chairman David Brennan said in a statement.

RELATED: Which biopharmas are best positioned for 2018? Leerink pegs Vertex and Alexion

At least one analyst likely wasn’t surprised to see activists jump into the mix at Alexion, which spent 2017 working to find its footing after key leaders departed amid a late-2016 sales-fraud investigation. Leerink Partners’ Geoffrey Porges has called the biotech “one of the rare, once or twice per decade, activist investment situations in the biopharmaceutical industry.”

Elliott, though, seems to like what it’s seen over the last couple of months from Hantson, whose moves have included hundreds of layoffs and a headquarters relocation. “We are encouraged by actions taken under Ludwig's leadership to improve financial performance and reset Alexion's strategy,” a spokesperson said in a statement.

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.